provided written informed cons ent prior to participation. This study was conducted in accordance with the Declaration ofHelsinki (1946), including the current Seoul revision (2008), andconsistent with Good Clinical Practice and applicable laws andregulations. Outcomes Study endpoints included change from baseline to weeks 26 and52, and change from week 26 to week 52, in HbA 1c,p a t i e n t s achieving HbA 1ctargets of < 7.0% (< 53 mmol ⁄mol) and £6.5% ( £48 mmol ⁄mol), change in fasting plasma glucose (target £7 mmol ⁄l), body weight, fasting li pids, fasting insulin, systolic and diastolic blood pres sure, cardiovascular risk markers (urinary albumin ⁄creatinine ratio, B-t ype natriuretic peptide, high-sensitivity C-reactive pr otein and plasminogen activator inhibitor-1), safety and toler ability. Plasma and urine analytes and HbA 1cwere quantitated by Quintiles Laboratories